The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a new evaluation tool.

Senate Democrats and the Biden administration dropped plans to set drug price caps based on the amount paid in other high-income countries, during talks years ago to push through the law that empowered Medicare to negotiate down the cost of prescription medications.

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

President Trump on Monday called on drugmakers to lower their prices within the next month to be closer to those charged in other high-income countries, threatening to subject them to steep caps on how much they can earn from Medicare if they fail to do so.

It’s unclear what — if any — impact the Republican president’s executive order will have on millions of Americans who have private health insurance.

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is not well aligned with FDA’s authority to regulate drug safety and efficacy.

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did

In January, Medicare named an additional batch of 15 drugs subject to negotiation this year. Those included blockbuster diabetes and weight loss drugs Ozempic and Wegovy, a cost-saving move that ...

As he launches a North American stadium tour and his "Hurry Up Tomorrow" film, Abel Tesfaye reflects on losing his voice onstage in 2022 and his decision to stop using his longtime stage name of The Weeknd. (May 7) The days of unlimited Medicare prescription drug costs are finally over.